Overview

A Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

Status:
Not yet recruiting

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Insmed Incorporated

Treatments:

Treprostinil